Probatebeta
Target

CD274

Programmed cell death 1 ligand 1

As of the edition of 20 October 2026, CD274 (programmed cell death 1 ligand 1, UniProt Q9NZQ7) has 46 drugs tested at it and 68 companies on the list, 13 on route A and 5 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
Q9NZQ7
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
80
Disease areas
Cancer; Lungs and airways; Digestive system; Urinary and reproductive; Pregnancy and women's health; Skin and connective tissue; Hormones; Blood and lymph
Registered trials of its drugs
2,535

Drugs at this target

StatusCount
Marketed5
Active16
Went quiet1
Stopped13
Status not established11
Total46
DrugStatusFurthest phaseUS protection
DurvalumabMarketedPhase 4Ends 2031
AtezolizumabMarketedPhase 4Ends 2029
AvelumabMarketedPhase 3Ends 2029
AdebrelimabActivePhase 4none listed
IvonescimabActivePhase 4none listed
EnvafolimabStoppedPhase 4none listed
BenmelstobartActivePhase 4none listed
Retlirafusp alfaActivePhase 3none listed
Bintrafusp alfaStoppedPhase 3none listed
ErfonrilimabActivePhase 3none listed
SugemalimabMarketedPhase 3none listed
HLX43ActivePhase 3none listed

12 of 46 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A13
Route B5
Engaged39
Undetermined11
Total on the list68
Three companies on route A or B, with the route only
CompanyRoute
AstraZenecaRoute B
IncyteRoute A
RocheRoute B

The other 65 companies at CD274

In the product

68 companies in all; 65 are not named here, and no score is.

See the 68 companies at CD274, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at CD274

Other targets in cancer

Companies holding approvals at CD274